Neurochemical Imaging and Depressive Behaviours

Current Topics in Behavioral Neurosciences

Volumn 14, Issue , 2013, Pages 101-134

  Meyer, Jeffrey H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Chaires de recherche du Canada   (Canada)

Author keywords

Dopamine transporter glutamate; Dopamine2 receptors; Major depressive disorder; Monoamine oxidase A; Serotonin transporter; Serotonin1a receptors; Serotonin2A receptors

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; DEXFENFLURAMINE; DOPAMINE 2 RECEPTOR; ESTRADIOL; ESTRIOL; EXCITATORY AMINO ACID TRANSPORTER; GLUCOSE TRANSPORTER 5; GLUTAMIC ACID; GLUTAMINE; HARMINE; HARMINE C 11; MONOAMINE; NEUROTRANSMITTER; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTERIOR CINGULATE; ANXIETY; ANXIETY DISORDER; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; BRAIN TISSUE; CINGULATE GYRUS; CORPUS STRIATUM; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE MARKER; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME METABOLISM; GRAY MATTER; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; INTRACELLULAR SIGNALING; LOCOMOTION; MAJOR DEPRESSION; MESENCEPHALON; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; MOOD CHANGE; MOOD DISORDER; MOTOR RETARDATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCIPITAL CORTEX; ORBITAL CORTEX; PARKINSON DISEASE; PATHOPHYSIOLOGY; PESSIMISM; PLASMA HALF LIFE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PUERPERAL DEPRESSION; PUERPERIUM; RECEPTOR BINDING; REGULATORY MECHANISM; RISK ASSESSMENT; SMOKING CESSATION; SYMPTOMATOLOGY; THALAMUS; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; DEPRESSIVE DISORDER; HUMANS; NEUROIMAGING;

EID: 84880051611     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2012_219     Document Type: Article

References (176)

1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. IV edn. Washington, DC. Am Psychiatr Assoc 387
2. Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL (1990) Depression and the dynamics of smoking a national perspective. JAMA 264:1541-1545
3. Arango V, Ernsberger P, Marzuk PM, Chen JS, Tierney H, Stanley M, Reis DJ, Mann JJ (1990) Autoradiographic demonstration of increased serotonin 5-HT2 and betaadrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 47:1038-1047
4. Arango V, Underwood M, Mann J (1992) Alterations in monoamine receptors in the brain of suicide victims. J Clin Psychopharm 12:8S-12S
5. Arango V, Underwood MD, Boldrini M, Tamir H, Kassir SA, Hsiung S, Chen JJ, Mann JJ (2001) Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuro psychopharmacol 25:892-903
6. Arora RC, Meltzer HY (1989) Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry 146:730-736
7. Attar-Levy D, Martinot J-L, Blin J, Dao-Castellana M-H, Crouzel C, Mazoyer B, Poirer M-F, Bourdel M-C, Aymard N, Syrota A, Feline A (1999) The cortical serotonin2 receptors studied with positron emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry 45:180-186
8. Austin MC, Whitehead RE, Edgar CL, Janosky JE, Lewis DA (2002) Localized decrease in serotonin transporter-immunoreactive axons in the prefrontal cortex of depressed subjects committing suicide. Neuroscience 114:807-815
9. Bacher I, Houle S, Xu X, Zawertailo L, Soliman A, Wilson AA, Selby P, George TP, Sacher J, Miler L, Kish SJ, Rusjan P, Meyer JH (2011) Monoamine oxidase a binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch Gen Psychiatry 68:817-826
10. Barbee JG, Jamhour NJ (2002) Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 63:737-741
11. Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, Thompson PM, Shelton RC (2011) A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 72:1405-1412
12. Barraclough B, Bunch J, Nelson B, Sainsbury P (1974) A hundred cases of suicide: clinical aspects. Br J Psychiatry 125:355-373
13. Barton DA, Esler MD, Dawood T, Lambert EA, Haikerwal D, Brenchley C, Socratous F, Hastings J, Guo L, Wiesner G, Kaye DM, Bayles R, Schlaich MP, Lambert GW (2008) Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch Gen Psychiatry 65:38-46
14. Beck A, Steer R, Kovacs M, Garrison B (1985) Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry 142(5):559-563
15. Beck AT, Brown G, Steer RA (1989) Prediction of eventual suicide in psychiatric inpatients by clinical ratings of hopelessness. J Consult Clin Psychol 57:309-310
16. Benmansour S, Cecchi M, Morilak D, Gerhardt G, Javors M, Gould G, Frazer A (1999) Effects of chronic antidepressant treatments on serotonin transporter function. Density mRNA Level J Neurosci 19(23):10494-10501
17. Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ (2004) Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 9:386-392
18. Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P, Grasby P (2006) Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am J Psychiatry 163:1580-1587
19. Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J (1997) Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br J Psychiatry 171:444-448
20. Blier P, Galzin AM, Langer SZ (1989) Diurnal variation in the function of serotonin terminals in the rat hypothalamus. J Neurochem 52:453-459
21. Bligh-Glover W, Kolli TN, Shapiro-Kulnane L, Dilley GE, Friedman L, Balraj E, Rajkowska G, Stockmeier CA (2000) The serotonin transporter in the midbrain of suicide victims with major depression. Biol Psychiatry 47:1015-1024
22. Bouvard M, Charles S, Guerin J, Aimard G, Cottraux J (1992) Study of beck's hopelessness scale. validation and factor analysis. Encephale 18:237-240
23. Breslau N, Peterson EL, Schultz LR, Chilcoat HD, Andreski P (1998) Major depression and stages of smoking a longitudinal investigation. Arch Gen Psychiatry 55:161-166
24. Brockington IF, Cernik KF, Schofield EM, Downing AR, Francis AF, Keelan C (1981) Puerperal psychosis phenomena and diagnosis. Arch Gen Psychiatry 38:829-833
25. Brucke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I (1993) SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. binding kinetics in the human brain. J Neural Transm Gen Sect 94:137-146
26. Brunswick DJ, Amsterdam JD, Mozley PD, Newberg A (2003) Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging. Am J Psychiatry 160:1836-1841
27. Buchert R, Schulze O, Wilke F, Berding G, Thomasius R, Petersen K, Brenner W, Clausen M (2006) Is correction for age necessary in SPECT or PET of the central serotonin transporter in young, healthy adults? J Nucl Med 47:38-42
28. Buck A, Gucker PM, Schonbachler RD, Arigoni M, Kneifel S, Vollenweider FX, Ametamey SM, Burger C (2000) Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: assessment of methods. J Cereb Blood Flow Metab 20:253-262
29. Cane D, Olinger L, Gotlib I, Kuiper N (1986) Factor structure of the dysfunctional attitude scale in a student population. J Clin Psychol 42:307-309
30. Cannon B, Mulroy R, Otto MW, Rosenbaum JF, Fava M, Nierenberg AA (1999) Dysfunctional attitudes and poor problem solving skills predict hopelessness in major depression. J Affect Disord 55:45-49
31. Cannon DM, Ichise M, Rollis D, Klaver JM, Gandhi SK, Charney DS, Manji HK, Drevets WC (2007) Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [(11)C]DASB; comparison with bipolar disorder. Biol Psychiatry 62:870-877
32. Carey MP, Kalra DL, Carey KB, Halperin S, Richards CS (1993) Stress and unaided smoking cessation: a prospective investigation. J Consult Clin Psychol 61:831-838
33. Carlsson A, Svennerholm L, Winblad B (1980) Seasonal and circadian monoamine variations in human brains examined post mortem. Acta Psychiatr Scand Suppl 280:75-85
34. Carroll FI, Kotian P, Dehghani A, Gray JL, Kuzemko MA, Parham KA, Abraham P, Lewin AH, Boja JW, Kuhar MJ (1995) Cocaine and 3 beta-(4′-substituted phenyl)tropane-2 betacarboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 38:379-388
35. Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW, Mufson EJ, Mash DC, Levey AI (1999) Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409:38-56
36. Crow TJ, Cross AJ, Cooper SJ, Deakin JF, Ferrier IN, Johnson JA, Joseph MH, Owen F, Poulter M, Lofthouse R et al (1984) Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 23:1561-1569
37. DeRubeis RJ, Evans MD, Hollon SD, Garvey MJ, Grove WM, Tuason VB (1990) How does cognitive therapy work? Cognitive change and symptom change in cognitive therapy and pharmacotherapy for depression. J Consult Clin Psychol 58:862-869
38. Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A, Burger C, Auberson YP, Sovago J, Stockmeier CA, Buck A, Hasler G (2011) Reduced metabotropic glutamate receptor 5 density in major depression determined by [11C]ABP688 PET and postmortem study. Am J Psychiatry 168:727-734
39. Dewar KM, Grondin L, Carli M, Lima L, Reader TA (1992) [3H]paroxetine binding and serotonin content of rat cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region following p-chlorophenylalanine and p-chloroamphetamine treatment. J Neurochem 58:250-257
40. D-haenen H, Bossuyt A, Mertens J, Bossuyt-Piron C, Gijesmans M, Kaufman L (1992) SPECT imaging of serotonin2 receptors in depression. Psychiatry Res Neuroimaging 45:227-237
41. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, Huang Y, Gautier C, Mathis C (1999) PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46:1375-1387
42. Elliott R, Rubinsztein JS, Sahakian BJ, Dolan RJ (2002) The neural basis of mood-congruent processing biases in depression. Arch Gen Psychiatry 59:597-604
43. Fava M, Bless E, Otto M, Pava J, Rosenbaum J (1994) Dysfunctional attitudes in major depression changes with pharmacotherapy. J Nerv Ment Dis 182(1):45-49
44. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulkova I, Wolf AP (1996) Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A 93:14065-14069
45. Freis ED (1954) Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med 251:1006-1008
46. Frokjaer VG, Mortensen EL, Nielsen FA, Haugbol S, Pinborg LH, Adams KH, Svarer C, Hasselbalch SG, Holm S, Paulson OB, Knudsen GM (2008) Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry 63:569-576
47. Garvey AJ, Bliss RE, Hitchcock JL, Heinold JW, Rosner B (1992) Predictors of smoking relapse among self-quitters: a report from the normative aging study. Addict Behav 17:367-377
48. Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S (2001) Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 21:1342-1353
49. Gordon I, Weizman R, Rehavi M (1996) Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 298:27-30
50. Graham D, Tahraoui L, Langer SZ (1987) Effect of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on [3H]paroxetine binding to cerebral cortical membranes of the rat. Neuropharmacology 26:1087-1092
51. Han S, Rowell PP, Carr LA (1999) D2 autoreceptors are not involved in the down-regulation of the striatal dopamine transporter caused by alpha-methyl-p-tyrosine. Res Commun Mol Pathol Pharmacol 104:331-338
52. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC (2007) Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64:193-200
53. Hasler G, Fromm S, Carlson PJ, Luckenbaugh DA, Waldeck T, Geraci M, Roiser JP, Neumeister A, Meyers N, Charney DS, Drevets WC (2008) Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry 65:521-531
54. Hendricksen M, Thomas AJ, Ferrier IN, Ince P, O'Brien JT (2004) Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression. Am J Psychiatry 161:1096-1102
55. Herold N, Uebelhack K, Franke L, Amthauer H, Luedemann L, Bruhn H, Felix R, Uebelhack R, Plotkin M (2006) Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [(123)I]-ADAM. J Neural Transm 113:659-670
56. Houle S, Ginovart N, Hussey D, Meyer J, Wilson A (2000) Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med 27:1719-1722
57. Hoyer D, Pazos A, Probst A, Palacios JM (1986) Serotonin receptors in the human brain. II. characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res 376:97-107
58. Hrdina P, Vu T (1993) Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: an autoradiographic study. Synapse 14:324-331
59. Hrdina P, Foy B, Hepner A, Summers R (1990) Antidepressant binding sites in brain: autoradiographic comparison of [3H]paroxetine and [3H]imipramine localization and relationship to serotonin transporter. J Pharm Exp Ther 252:410-418
60. Ichimiya T, Suhara T, Sudo Y, Okubo Y, Nakayama K, Nankai M, Inoue M, Yasuno F, Takano A, Maeda J, Shibuya H (2002) Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652. Biol Psychiatry 51:715-722
61. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, Suhara T, Suzuki K, Innis RB, Carson RE (2003) Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096-1112
62. Ikawa K, Watanabe A, Kaneno S, Toru M (1993) Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents. Eur J Pharmacol 250:261-266
63. Ikoma Y, Suhara T, Toyama H, Ichimiya T, Takano A, Sudo Y, Inoue M, Yasuno F, Suzuki K (2002) Quantitative analysis for estimating binding potential of the brain serotonin transporter with [11 C]McN5652. J Cereb Blood Flow Metab 22:490-501
64. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S et al (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A 90:11965-11969
65. Joensuu M, Tolmunen T, Saarinen PI, Tiihonen J, Kuikka J, Ahola P, Vanninen R, Lehtonen J (2007) Reduced midbrain serotonin transporter availability in drug-naive patients with depression measured by SERT-specific [(123)I] nor-beta-CIT SPECT imaging. Psychiatry Res 154:125-131
66. Johnson S, Stockmeier CA, Meyer JH, Austin MC, Albert PR, Wang J, May WL, Rajkowska G, Overholser JC, Jurjus G, Dieter L, Johnson C, Sittman DB, Ou XM (2011) The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder. Neuropsychopharmacology 36(10):2139-2148
67. Kasper S, Wehr TA, Bartko JJ, Gaist PA, Rosenthal NE (1989) Epidemiological findings of seasonal changes in mood and behavior. A telephone survey of Montgomery county. Md Arch Gen Psychiatry 46:823-833
68. Kendell RE, Chalmers JC, Platz C (1987) Epidemiology of puerperal psychoses. Br J Psychiatry 150:662-673
69. Kenford SL, Smith SS, Wetter DW, Jorenby DE, Fiore MC, Baker TB (2002) Predicting relapse back to smoking: contrasting affective and physical models of dependence. J Consult Clin Psychol 70:216-227
70. Kent JM, Coplan JD, Lombardo I, Hwang DR, Huang Y, Mawlawi O, Van Heertum RL, Slifstein M, Abi-Dargham A, Gorman JM, Laruelle M (2002) Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652. Psychopharmacology (Berl) 164:341-348
71. Kilbourn MR, Sherman PS, Pisani T (1992) Repeated reserpine administration reduces in vivo [18F]GBR 13119 binding to the dopamine uptake site. Eur J Pharmacol 216:109-112
72. Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, Lang AE (2002) Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 17:303-312
73. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318:876-880
74. Klimek V, Roberson G, Stockmeier CA, Ordway GA (2003) Serotonin transporter and MAO-B levels in monoamine nuclei of the human brainstem are normal in major depression. J Psychiatr Res 37:387-397
75. Konradi C, Svoma E, Jellinger K, Riederer P, Denney R, Thibault J (1988) Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem. Neuroscience 26:791-802
76. Konradi C, Kornhuber J, Froelich L, Fritze J, Heinsen H, Beckmann H, Schulz E, Riederer P (1989) Demonstration of monoamine oxidase-A and B in the human brainstem by a histochemical technique. Neuroscience 33:383-400
77. Kontur PJ, al-Tikriti M, Innis RB, Roth RH (1994) Postmortem stability of monoamines, their metabolites, and receptor binding in rat brain regions. J Neurochem 62:282-290
78. Korf J, Praag HMV (1971) Retarded depression and the dopamine metabolism. Psychopharmacologia 19:199-203
79. Koskela A, Kauppinen T, Keski-Rahkonen A, Sihvola E, Kaprio J, Rissanen A, Ahonen A (2008) Brain serotonin transporter binding of [123I]ADAM: within-subject variation between summer and winter data. Chronobiol Int 25:657-665
80. Kuikka JT, Bergstrom KA, Vanninen E, Laulumaa V, Hartikainen P, Lansimies E (1993) Initial experience with single-photon emission tomography using iodine-123-labelled 2 betacarbomethoxy-3 beta-(4-iodophenyl) tropane in human brain. Eur J Nucl Med 20:783-786
81. Lambert GW, Reid C, Kaye DM, Jennings GL, Esler MD (2002) Effect of sunlight and season on serotonin turnover in the brain. Lancet 360:1840-1842
82. Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, Holik A, Attarbaschi T, Mossaheb N, Sacher J, Geiss-Granadia T, Kletter K, Kasper S, Tauscher J (2007) Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 61:1081-1089
83. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451
84. Laruelle M, Giddings SS, Zea-Ponce Y, Charney DS, Neumeyer JL, Baldwin RM, Innis RB (1994) Methyl 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under ''physiological'' conditions. J Neurochem 62:978-986
85. Law M, Tang JL (1995) An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 155:1933-1941
86. Lawrence KM, De Paermentier F, Cheetham SC, Crompton MR, Katona CL, Horton RW (1990) Brain 5-HT uptake sites, labelled with [3H]paroxetine, in antidepressant-free depressed suicides. Brain Res 526:17-22
87. Leake A, Fairbairn AF, McKeith IG, Ferrier IN (1991) Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: neurochemical and clinical correlates. Psychiatry Res 39:155-165
88. Linnet K, Koed K, Wiborg O, Gregersen N (1995) Serotonin depletion decreases serotonin transporter mRNA levels in rat brain. Brain Res 697:251-253
89. Liotti M, Mayberg HS, McGinnis S, Brannan SL, Jerabek P (2002) Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am J Psychiatry 159:1830-1840
90. Little KY, McLauglin DP, Ranc J, Gilmore J, Lopez JF, Watson SJ, Carroll FI, Butts JD (1997) Serotonin transporter binding sites and mRNA levels in depressed persons committing suicide. Biol Psychiatry 41:1156-1164
91. Luque JM, Kwan SW, Abell CW, Da Prada M, Richards JG (1995) Cellular expression of mRNAs encoding monoamine oxidases A and B in the rat central nervous system. J Comp Neurol 363:665-680
92. Magnusson A (2000) An overview of epidemiological studies on seasonal affective disorder. Acta Psychiatr Scand 101:176-184
93. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS (1998) Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography [see comments]. Biol Psychiatry 44:1090-1098
94. Malone KM, Oquendo MA, Haas GL, Ellis SP, Li S, Mann JJ (2000) Protective factors against suicidal acts in major depression: reasons for living. Am J Psychiatry 157:1084-1088
95. Mann JJ, Stanley M, McBride PA, McEwen BS (1986) Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 43:954-959
96. Mann J, Underwood M, Arango V (1996) Postmortem studies of suicide victims biology of schizophrenia and affective disorders. American Psychiatric Press, Washington, pp 197-221
97. Mann JJ, Huang YY, Underwood MD, Kassir SA, Oppenheim S, Kelly TM, Dwork AJ, Arango V (2000) A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide [see comments]. Arch Gen Psychiatry 57:729-738
98. Marazziti D, Rossi A, Giannaccini G, Zavaglia KM, Dell'Osso L, Lucacchini A, Cassano GB (1999) Distribution and characterization of [3H]mesulergine binding in human brain postmortem. Eur Neuropsychopharmacol 10:21-26
99. Meltzer C, Price J, Mathis C, Greer P, Cantwell M, Houck P, Mulsant B, Ben-Eliezer D, Lopresti B, DeKosky S, Reynolds C (1999) PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psych 156(12):1871-1878
100. Messa C, Colombo C, Moresco RM, Gobbo C, Galli L, Lucignani G, Gilardi MC, Rizzo G, Smeraldi E, Zanardi R, Artigas F, Fazio F (2003) 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berl) 167:72-78
101. Meyer JH (2007) Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 32:86-102
102. Meyer JH (2008) Applying neuroimaging ligands to study major depressive disorder. Semin Nucl Med 38:287-304
103. Meyer J, Kapur S, Houle S, DaSilva J, Owczarek B, Brown G, Wilson A, Kennedy S (1999) Prefrontal cortex 5-HT2 receptors in depression: a [18F] setoperone PET imaging study. Am J Psychiatry 156:1029-1034
104. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, Minifie C, Houle S, Hussey D, Kennedy SH (2001a) Lower dopamine transporter binding potential in striatum during depression. Neuroreport 12:4121-4125
105. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S (2001b) Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 158:1843-1849
106. Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, Wilson AA, Blak T, Eynan-Harvey R, Goulding VS, Houle S, Links P (2003) Dysfunctional attitudes and 5-HT(2) receptors during depression and self-harm. Am J Psychiatry 160:90-99
107. Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, Goulding V, Kennedy J, Wilson AA (2004a) Brain serotonin transporter binding potential measured with carbon 11labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 61:1271-1279
108. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004b) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826-835
109. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, Young T, Praschak-Rieder N, Wilson AA, Houle S (2006a) Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63:1209-1216
110. Meyer JH, McNeely HE, Sagrati S, Boovariwala A, Martin K, Verhoeff NP, Wilson AA, Houle S (2006b) Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry 163:1594-1602
111. Meyer JH, Wilson AA, Sagrati S, Miler L, Rusjan P, Bloomfield PM, Clark M, Sacher J, Voineskos AN, Houle S (2009) Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry 66:1304-1312
112. Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, Huang Y, Snyder AZ (2004) Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol Psychiatry 55:217-224
113. Moll G, Moll R, Riederer P, Gsell W, Heinsen H, Denney RM (1990) Immunofluorescence cytochemistry on thin frozen sections of human substantia nigra for staining of monoamine oxidase A and monoamine oxidase B: a pilot study. J Neural Transm Suppl 32:67-77
114. Nash JR, Sargent PA, Rabiner EA, Hood SD, Argyropoulos SV, Potokar JP, Grasby PM, Nutt DJ (2008) Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. Br J Psychiatry 193:229-234
115. Neumeister A, Pirker W, Willeit M, Praschak-Rieder N, Asenbaum S, Brucke T, Kasper S (2000) Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 47:158-160
116. Neumeister A, Willeit M, Praschak-Rieder N, Asenbaum S, Stastny J, Hilger E, Pirker W, Konstantinidis A, Kasper S (2001) Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med 31:1467-1473
117. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, Eckelman W, Herscovitch P, Charney DS, Drevets WC (2004a) Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 24:589-591
118. Neumeister A, Nugent AC, Waldeck T, Geraci M, Schwarz M, Bonne O, Bain EE, Luckenbaugh DA, Herscovitch P, Charney DS, Drevets WC (2004b) Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry 61:765-773
119. Newberg AB, Amsterdam JD, Wintering N, Ploessl K, Swanson RL, Shults J, Alavi A (2005) 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med 46:973-977
120. Norman W, Miller I, Dow M (1988) Characteristics of depressed patients with elevated levels of dysfunctional cognitions. Cog Ther Res 12:39-51
121. O'Hara MW, Swain A (1996) Rates and risk of postpartum depression-a meta analysis. Int Rev Psychiatry 8:37-54
122. O'Hara MW, Schlechte JA, Lewis DA, Wright EJ (1991) Prospective study of postpartum blues. Biologic and psychosocial factors. Arch Gen Psychiatry 48:801-806
123. Oliver J, Baumgart E (1985) The dysfunctional attitude scale: psychometric properties and relation to depression in an unselected adult population. Cog Ther Res 9:161-167
124. O'Regan D, Kwok RP, Yu PH, Bailey BA, Greenshaw AJ, Boulton AA (1987) A behavioural and neurochemical analysis of chronic and selective monoamine oxidase inhibition. Psychopharmacology 92:42-47
125. Ou XM, Chen K, Shih JC (2006) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci U S A 103:10923-10928
126. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Pandey SC, Pesold C, Roberts RC, Conley RR, Tamminga CA (2002) Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry 159:419-429
127. Parsey RV, Kegeles LS, Hwang DR, Simpson N, Abi-Dargham A, Mawlawi O, Slifstein M, Van Heertum RL, Mann JJ, Laruelle M (2000) In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. J Nucl Med 41:1465-1477
128. Parsey RV, Hastings RS, Oquendo MA, Huang YY, Simpson N, Arcement J, Huang Y, Ogden RT, Van Heertum RL, Arango V, Mann JJ (2006a) Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 163:52-58
129. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, Van Heertum RL, Arango V, Mann JJ (2006b) Altered serotonin 1A binding in major depression: a [carbonyl-C11]WAY100635 positron emission tomography study. Biol Psychiatry 59:106-113
130. Perry EK, Marshall EF, Blessed G, Tomlinson BE, Perry RH (1983) Decreased imipramine binding in the brains of patients with depressive illness. Br J Psychiatry 142:188-192
131. Post RM, Kotin J, Goodwin FK, Gordon EK (1973) Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness. Am J Psychiatry 130:67-72
132. Praag HM, Korf J, Lakke J, Schut T (1975) Dopamine metabolism in depressions, psychoses, and Parkinson's disease: the problem of the specificity of biological variables in behaviour disorders. Psychol Med 5:138-146
133. Praschak-Rieder N, Wilson AA, Hussey D, Carella A, Wei C, Ginovart N, Schwarz MJ, Zach J, Houle S, Meyer JH (2005) Effects of tryptophan depletion on the serotonin transporter in healthy humans. Biol Psychiatry 58:825-830
134. Praschak-Rieder N, Willeit M, Wilson AA, Houle S, Meyer JH (2008) Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry 65:1072-1078
135. Pratt L, Brody D (2010) Depression and smoking in the U.S. household population aged 20 and over, 2005-2008. NCHS Data Brief 34:1-8
136. Rajkowska G, Miguel-Hidalgo JJ (2007) Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 6:219-233
137. Robins E, Murphy G, Wilkinson R, Gassner S, Kayes J (1959) Some clinical considerations in the prevention of suicide based on a study of 134 successful suicides. Am J Publ Health 49(7):888-899
138. Rommelspacher H, Meier-Henco M, Smolka M, Kloft C (2002) The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur J Pharmacol 441:115-125
139. Rosen LN, Targum SD, Terman M, Bryant MJ, Hoffman H, Kasper SF, Hamovit JR, Docherty JP, Welch B, Rosenthal NE (1990) Prevalence of seasonal affective disorder at four latitudes. Psychiatry Res 31:131-144
140. Roth B, McLean S, Zhu X, Chuang D (1987) Characterization of two [3H]ketanserin recognition sites in rat striatum. J Neurochem 49:1833-1838
141. Rovescalli AC, Brunello N, Riva M, Galimberti R, Racagni G (1989) Effect of different photoperiod exposure on [3H]imipramine binding and serotonin uptake in the rat brain. J Neurochem 52:507-514
142. Ruhe HG, Mason NS, Schene AH (2007) Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12:331-359
143. Ruhe HG, Booij J, Reitsma JB, Schene AH (2009) Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging 36:841-849
144. Sacher J, Wilson A, Houle S, Hassan S, Rusjan P, Bloomfield P, Stewart D, Meyer J (2010) Elevated brain monoamine oxidase A binding in early postpartum. Arch Gen Psychiatry 67(5):468-474
145. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61:705-713
146. Sarchiapone M, Carli V, Camardese G, Cuomo C, Di Giuda D, Calcagni ML, Focacci C, De Risio S (2006) Dopamine transporter binding in depressed patients with anhedonia. Psychiatry Res 147:243-248
147. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, Gunn RN, Grasby PM, Cowen PJ (2000) Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57:174-180
148. Saura J, Kettler R, Da Prada M, Richards JG (1992) Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 12:1977-1999
149. Saura J, Bleuel Z, Ulrich J, Mendelowitsch A, Chen K, Shih JC, Malherbe P, Da Prada M, Richards JG (1996) Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience 70:755-774
150. Schmuck K, Ullmer C, Engels P, Lubbert H (1994) Cloning and functional characterization of the human 5-HT2B serotonin receptor. FEBS Lett 342:85-90
151. Selvaraj S, Venkatesha Murthy N, Bhagwagar Z, Bose SK, Hinz R, Grasby PM, Cowen PJ (2009) Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [(11)C]DASB. Psychopharmacology 213(2-3):555-562
152. Sharot T, Riccardi AM, Raio CM, Phelps EA (2007) Neural mechanisms mediating optimism bias. Nature 450:102-105
153. Simons AD, Murphy GE, Levine JL, Wetzel RD (1986) Cognitive therapy and pharmacotherapy for depression. Sustained improvement over one year. Arch Gen Psychiatry 43:43-48
154. Stanley M, Mann JJ (1983) Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1:214-216
155. Stockmeier CA (2003) Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatr Res 37:357-373
156. Stockmeier CA, Kellar KJ (1986) In vivo regulation of the serotonin-2 receptor in rat brain. Life Sci 38:117-127
157. Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, Meltzer HY (1997) Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 16:162-173
158. Stockmeier CA, Howley E, Shi X, Sobanska A, Clarke G, Friedman L, Rajkowska G (2009) Antagonist but not agonist labeling of serotonin-1A receptors is decreased in major depressive disorder. J Psychiatr Res 43:887-894
159. Todd KG, McManus DJ, Baker GB (1995) Chronic administration of the antidepressants phenelzine, desipramine, clomipramine, or maprotiline decreases binding to 5-hydroxytryptamine2A receptors without affecting benzodiazepine binding sites in rat brain. Cell Mol Neurobiol 15:361-370
160. Tom SM, Fox CR, Trepel C, Poldrack RA (2007) The neural basis of loss aversion in decisionmaking under risk. Science 315:515-518
161. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28-40
162. Turecki G, Briere R, Dewar K, Antonetti T, Lesage AD, Seguin M, Chawky N, Vanier C, Alda M, Joober R, Benkelfat C, Rouleau GA (1999) Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 156:1456-1458
163. Verhoeff NP, Kapur S, Hussey D, Lee M, Christensen B, Psych C, Papatheodorou G, Zipursky RB (2001) A simple method to measure baseline occupancy of neostriatal dopamine d(2) receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 25:213-223
164. Walter M, Henning A, Grimm S, Schulte RF, Beck J, Dydak U, Schnepf B, Boeker H, Boesiger P, Northoff G (2009) The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry 66:478-486
165. Weissman A (1979) The dysfunctional attitude scale: a validation study. Dissertation Abstr Int 40:1389B-1390B
166. Willeit M, Ginovart N, Graff A, Rusjan P, Vitcu I, Houle S, Seeman P, Wilson AA, Kapur S (2008) First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: a [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology 33:279-289
167. Wilson A, Schmidt M, Ginovart N, Meyer J, Houle S (2000) Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, in vitro and ex vivo evaluation of [11C]-labelled 2-(Phenylthio) araalkylamines. J Med Chem 43:3103-3110
168. Wilson AA, Ginovart N, Hussey D, Meyer J, Houle S (2002) In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol 29:509-515
169. World Health Organization (2008) The global burden of disease: 2004 update. Department of Health Statistics and Informatics, Information Evidence and Research Cluster, WHO, Geneva
170. Xiao Q, Pawlyk A, Tejani-Butt SM (1999) Reserpine modulates serotonin transporter mRNA levels in the rat brain. Life Sci 64:63-68
171. Yates M, Leake A, Candy JM, Fairbairn AF, McKeith IG, Ferrier IN (1990) 5HT2 receptor changes in major depression. Biol Psychiatry 27:489-496
172. Yatham LN, Liddle PF, Shiah IS, Scarrow G, Lam RW, Adam MJ, Zis AP, Ruth TJ (2000) Brain serotonin2 receptors in major depression: a positron emission tomography study. Arch Gen Psychiatry 57:850-858
173. Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295-309
174. Young SN, Smith SE, Pihl RO, Ervin FR (1985) Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 87:173-177
175. Yu A, Yang J, Pawlyk AC, Tejani-Butt SM (1995) Acute depletion of serotonin down-regulates serotonin transporter mRNA in raphe neurons. Brain Res 688:209-212
176. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 63:856-864